N
Google TrendNOVIG (2000+) — Novig Sign Up Bonus: ROTOWIRE Gets $50 in Trade Credits
The 24/7 Global Portal

World News, Markets & Google Trends

Aggregated real-time headlines, trending Google search queries, and verified dispatches in one single page.

Google Trends:novig2000+boise state vs fresno state500+sounders500+pedro pascal200+medicare2000+blade200+kings vs golden knights1000+white sox vs cleveland guardians match player stats1000+
Category:All HeadlinesWorld & GeopoliticsMarkets & EconomyTech & AIPoliticsSearch results for: "Achieving clinically mean" (30 stories)

Top Headline Story

Achieving clinically meaningful outcomes in digital health: a six-step, cyclical precision engagement framework (ENGAGE)
Lead StoryFrontiersscience
Jan 13

Achieving clinically meaningful outcomes in digital health: a six-step, cyclical precision engagement framework (ENGAGE)

<a href="https://news.google.com/rss/articles/CBMilwFBVV95cUxNZGJ6ZjdGYlhyVTh3RlFaSkw0a0lIYWphZEdmWXpTRmUtdGtfcGxpVHZVZE5aME4wUHZhTXJsWjRxT2oxYnJwb1hTNFdGUTBtVnVGNFd1dTdRQWpBZm9qMkdKNFJaZ0MtczlFcUhaaDZteTVLbFBXZThwSVRTcFJXMDg3Rnc4d3pIUjZPQlNPeXR5Yi1oTEln?oc=5" target="_blank">Achieving clinically meaningful outcomes in digital health: a six-step, cyclical precision engagement framework (ENGAGE)</a>  <font color="#6f6f6f">Frontiers</font>

Read Full StoryRelated Trends

Google Trends & Trending Search Intelligence

Real-time search volume
2000+22m ago

novig

Novig Sign Up Bonus: ROTOWIRE Gets $50 in Trade Credits

Filter stories
500+22m ago

boise state vs fresno state

Boise State gets big health boost, but injury concerns remain vs. Fresno State

Filter stories
500+22m ago

sounders

NEvsSEA Starting XI: Dejan Joveljić and Yeimar return to starting lineup, Sebastian Gomez gets the nod

Filter stories
200+22m ago

pedro pascal

Pedro Pascal in ‘Behemoth!’: The Oscar-Worthy Role That He (and Latinos) Have Been Waiting For

Filter stories

Search Results for "Achieving clinically mean"

Updated every 3 minutes via FreeNewsApi, GNews, Currents API & Google News

29 stories displayed
Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial
Naturetech

Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE1VeTcySUgzbHhHaDFNdmhMZXlCYzNYNF9ZTmJiU0ZJVDhPMzF1ZS1Fdm5sQWZua2h0djRBMFRHVUxsVHN4QXM2S1A3NTctVTRBVUdHdnNpR3U1TUU3WEs0?oc=5" target="_blank">Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Multi-Model Clinical Validation of an AI-Powered Biomarker Analysis Framework: A Cross-Vendor Benchmark on 4,018 NHANES Patients
medRxivtech

Multi-Model Clinical Validation of an AI-Powered Biomarker Analysis Framework: A Cross-Vendor Benchmark on 4,018 NHANES Patients

<a href="https://news.google.com/rss/articles/CBMic0FVX3lxTFBYQzlpUzZUM3ljR19fZHlrazlfZ0kzRmlDbThTU19La19oSFF4TWxpUjBzNzZBaFE1emlKRWl0bnlqZ2ZoV0dpRG8yV19ZYTREMlZLbDhINXNURDBfSFNHMmUxTXNKdTlPUS1FS2tzdFU3Ylk?oc=5" target="_blank">Multi-Model Clinical Validation of an AI-Powered Biomarker Analysis Framework: A Cross-Vendor Benchmark on 4,018 NHANES Patients</a>  <font color="#6f6f6f">medRxiv</font>

Read Full StoryMore like this
Bepirovirsen Achieves Clinically Meaningful Functional Cure Rates in Chronic Hepatitis B
AJMCworld

Bepirovirsen Achieves Clinically Meaningful Functional Cure Rates in Chronic Hepatitis B

<a href="https://news.google.com/rss/articles/CBMitAFBVV95cUxNWWo2THNvMnhkUUdQZ2VXV2dNWS1OcjFJWERDQnpMZmI4dENhM0p3N2ZTWW4yTzB4RGZXNUk5LVFBdVc4X2JkcENvSW5qVkdmaklFbm1kSWZNQ3lKaHhTUm1heXNKSURmSDBNSk0zUnFVTW0yV2Eta1prbWFSNVVTSGRxNU90RFE1Uy1WSjhlQU9JMkphMGJIVXQwbHFoeDROS290VkVIeU80TGRSZm1Kc3RPdUQ?oc=5" target="_blank">Bepirovirsen Achieves Clinically Meaningful Functional Cure Rates in Chronic Hepatitis B</a>  <font color="#6f6f6f">AJMC</font>

Read Full StoryMore like this
Habitual pork consumption supports clinically meaningful weight loss, study finds
News-Medicalgeneral

Habitual pork consumption supports clinically meaningful weight loss, study finds

<a href="https://news.google.com/rss/articles/CBMixwFBVV95cUxQaU53UTZaa0FDZEs2MWpxNXQyVEswRkhMUWNManB6aEFiMEIwU1gtejZ2TGpCanJFeDZYU0w1dGZ4eE56VGxGZVlPRUd4TnBIbndyQWw4VlN0QUxUa2U5NXVCbXU0MDQ0ZlJIem94TEFuYk9JTjkyWTQ2QW54U253bXFZY21ZdVRoZmJRV29nZVJtTk1HakozWlRGQTd3bGlkMUxjaDRmS1NDdXprWHJzRWdWYkF4LTB6YjV5LXZzcExyZVBmM05V?oc=5" target="_blank">Habitual pork consumption supports clinically meaningful weight loss, study finds</a>  <font color="#6f6f6f">News-Medical</font>

Read Full StoryMore like this
A trial that fails to reach its clinical endpoints isn’t necessarily a ‘failure’
Cystic Fibrosis News Todaytech

A trial that fails to reach its clinical endpoints isn’t necessarily a ‘failure’

<a href="https://news.google.com/rss/articles/CBMiqgFBVV95cUxNWkxlWU1uZDA5MnpNdko1MFZoVGFWMFNCenFuc3lBdWxPakxibXlEYkJpOEQzNHBBRFp1ZmdzNDVGV1htZlIwTFdERzZyaGtLZmVSbHpNR280aDRLWGxIM2tMVXRzS0Frcjc3cXVXaHlTS1Uwak9HdDZqdnRDM0JUOVh5MUxVR3pwdWlnczRULVg4Y245ampqV0dBODBtUllFU1NsVDdqVWhrdw?oc=5" target="_blank">A trial that fails to reach its clinical endpoints isn’t necessarily a ‘failure’</a>  <font color="#6f6f6f">Cystic Fibrosis News Today</font>

Read Full StoryMore like this
Biohaven Reports Positive Clinical Biomarker and Patient Data: First MoDE and TRAP Extracellular Protein Degraders Achieve Deep, Rapid, Selective Lowering of Disease-Driving Antibodies in Graves' Disease and IgA Nephropathy
PR Newswiregeneral

Biohaven Reports Positive Clinical Biomarker and Patient Data: First MoDE and TRAP Extracellular Protein Degraders Achieve Deep, Rapid, Selective Lowering of Disease-Driving Antibodies in Graves' Disease and IgA Nephropathy

<a href="https://news.google.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?oc=5" target="_blank">Biohaven Reports Positive Clinical Biomarker and Patient Data: First MoDE and TRAP Extracellular Protein Degraders Achieve Deep, Rapid, Selective Lowering of Disease-Driving Antibodies in Graves' Disease and IgA Nephropathy</a>  <font color="#6f6f6f">PR Newswire</font>

Read Full StoryMore like this
Arrowhead Pharmaceuticals Announces Interim Clinical Data on RNAi-based Obesity Candidates Showing Weight Loss in Obese Patients with Diabetes and Improved Measures of Body Composition
Arrowhead Pharmaceuticals, Inc.tech

Arrowhead Pharmaceuticals Announces Interim Clinical Data on RNAi-based Obesity Candidates Showing Weight Loss in Obese Patients with Diabetes and Improved Measures of Body Composition

<a href="https://news.google.com/rss/articles/CBMixwFBVV95cUxQQkJXcjZsRm9KellqSFE4TVRyZW8wQ0M2eTc3WTZIUTQ0Y25lZUtpc1dBNDMtTEZMSUtXZmZsZjdYYml1S003S0JQdjJaYkI5XzRNV0YxeVZFSk1xMER2OFV4aEIyVzVNT3BtTkg4bWhiUFY3S2RON3p4ZmZOQkpQU3RBdC1oNFRNQjNIend4RnJqZnNpY2JLRi1jYnd4MklUbWQ4UHpkRGNUZU9fMlBsWmcyX21RcWR4UmtiNGk4NjhaMzh1a2tj?oc=5" target="_blank">Arrowhead Pharmaceuticals Announces Interim Clinical Data on RNAi-based Obesity Candidates Showing Weight Loss in Obese Patients with Diabetes and Improved Measures of Body Composition</a>  <font color="#6f6f6f">Arrowhead Pharmaceuticals, Inc.</font>

Read Full StoryMore like this
Achieving best-in-class clinical trial delivery: The road to 2035
McKinsey & Companygeneral

Achieving best-in-class clinical trial delivery: The road to 2035

<a href="https://news.google.com/rss/articles/CBMixgFBVV95cUxPYm9SeFg0U0xjSlo1dkw5TF9ZSEZZUGxIMThTOFUzUEl3MVlGMEJ3aVlXT3Bvbk5uQnpmcGtIMjJiSENoR0pDZXlOeU5xS0d5VFJSVVBVdWRmcEZWbDlUbWI3cGhQUVFuMGdxYlVBZnh2QnFXOVljMVRRWHh3NlNQM25VMkZRQ0RxOTQ1UmE1TWkzdXdrLS1obm9Rd2VZYTBCQ2t2dFU0b0RfUkpHZDlIT0I4M0Vpd1o5R0FyeHFzVWQ4eVhlNXc?oc=5" target="_blank">Achieving best-in-class clinical trial delivery: The road to 2035</a>  <font color="#6f6f6f">McKinsey & Company</font>

Read Full StoryMore like this
New Research Shows Ro Helps Patients Achieve Weight Loss and Safety Outcomes Consistent with Clinical Trials
Rogeneral

New Research Shows Ro Helps Patients Achieve Weight Loss and Safety Outcomes Consistent with Clinical Trials

<a href="https://news.google.com/rss/articles/CBMiTkFVX3lxTE45YjhIUUpuemc4QVVZbnlxR2dhNXVlRm5fYUdWNEJBYU9KTVZhWjlCaVJMLVZlQ3A5eGpfTXFnV1dPN2dHMFAtRWJZRTVHUQ?oc=5" target="_blank">New Research Shows Ro Helps Patients Achieve Weight Loss and Safety Outcomes Consistent with Clinical Trials</a>  <font color="#6f6f6f">Ro</font>

Read Full StoryMore like this
Baxdrostat demonstrated a statistically significant and highly clinically meaningful placebo-adjusted reduction of 14.0 mmHg in 24-hour ambulatory systolic blood pressure in patients with resistant hypertension in the Bax24 Phase III trial
AstraZenecageneral

Baxdrostat demonstrated a statistically significant and highly clinically meaningful placebo-adjusted reduction of 14.0 mmHg in 24-hour ambulatory systolic blood pressure in patients with resistant hypertension in the Bax24 Phase III trial

<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxOUUlEZmFyVHhSLUJuZDNpZWZnd3haQnVkRXA0T0laWVhaQ1I1QS1Od2ZQS1dKQU83N2UxcU9WZUJPdV96RFo0NlhtbDVEWWNjUnZDNUFTa1o5VGplUXVIWnkyYUJ0VEI2aW1iLVExNTF5S2pMM3pjMk9JOHdOV3hMb3lMbVlsb29NY1U0Z3VfdnRNdkhMYUN0Q2hPdlRKR09EbkE?oc=5" target="_blank">Baxdrostat demonstrated a statistically significant and highly clinically meaningful placebo-adjusted reduction of 14.0 mmHg in 24-hour ambulatory systolic blood pressure in patients with resistant hypertension in the Bax24 Phase III trial</a>  <font color="#6f6f6f">AstraZeneca</font>

Read Full StoryMore like this
Government drives forward its 150-day clinical trial target
GOV.UKgeneral

Government drives forward its 150-day clinical trial target

<a href="https://news.google.com/rss/articles/CBMimgFBVV95cUxPS1F0S3FkcVpiUHpCVzNIcWFTRU1LYnlBQUNxNXBFbVhnY0s1bXU2b19PaHNVMW1EckNCaXloWjh0WUVYNXR0RlRTWjh0eVFRdEJVbXZiTk1lRjZCTlpmX2ZMOGhnZEZUd3ZBOFRxczFlcmd3N3B0RVFBaElVaFdsSjZWcFRHMWFud0VkWnZSbS1QYm1SNXdjdzJ3?oc=5" target="_blank">Government drives forward its 150-day clinical trial target</a>  <font color="#6f6f6f">GOV.UK</font>

Read Full StoryMore like this
Retatrutide Achieves Up to 30.3% Average Weight Loss in Phase 3 TRIUMPH-1 Trial
AJMCgeneral

Retatrutide Achieves Up to 30.3% Average Weight Loss in Phase 3 TRIUMPH-1 Trial

<a href="https://news.google.com/rss/articles/CBMipwFBVV95cUxNdWRka1luTlNsT2Y0V3Y3aG9ZbS1aY2tndmZpcHpvTXd3eDlBeDhRaG9IQ1hka3RLVUV5amlBUW5fSHBSTk5kRXVSVFpJdFoxZDhvOUFQOGh1cXB5V1piRTVkM0VTQWpJd2poWHR4V2FBVFVfS0o0ZndTMldXX0VZcHpOeFNyeElPdEpBUHpTYXRMR1FFN0VxQjBxaEhkMllvTGRHVmphbw?oc=5" target="_blank">Retatrutide Achieves Up to 30.3% Average Weight Loss in Phase 3 TRIUMPH-1 Trial</a>  <font color="#6f6f6f">AJMC</font>

Read Full StoryMore like this
Clinical Contact Center surpasses national standards in February | VA Tuscaloosa health care | Veterans Affairs
VA.gov Home | Veterans Affairstech

Clinical Contact Center surpasses national standards in February | VA Tuscaloosa health care | Veterans Affairs

<a href="https://news.google.com/rss/articles/CBMitgFBVV95cUxQZ1NXbGNkVmdJMnpaMXFValVHbmRRY2pPZ0JndFlSQy0tal9DeXgzbEVFX21FNDJCOTJkN1ZlUDdKNkhVODVVTGFPd1hzcHhMWTYxcHJENXZOTnJDLXIyQ1ZIajBQSGNpRlAwa1ItU2ZTbjJiREczSnFKSmQzQjJoVnphNXZCYmdURUZSandrTFpKbnFCSFhVNFdKZGV3a1NlMy1haG90WmFiSjl6SF9SOGdlNTNMdw?oc=5" target="_blank">Clinical Contact Center surpasses national standards in February | VA Tuscaloosa health care | Veterans Affairs</a>  <font color="#6f6f6f">VA.gov Home | Veterans Affairs</font>

Read Full StoryMore like this
How Can Radiopharmaceutical Therapies Reach Their Full Potential? Improving Dose Reporting and Phase I Clinical Trial Design
ASCO Publicationsgeneral

How Can Radiopharmaceutical Therapies Reach Their Full Potential? Improving Dose Reporting and Phase I Clinical Trial Design

<a href="https://news.google.com/rss/articles/CBMiWEFVX3lxTE9UVVZ1em44alFkVk95ckxtbUZZT05SbVQxVTJ2ckJNLTNxUzUyMWJSU0Nsa2pXRDJVcXpkWGpZYjd5UC02andlakxBUmk3Yy16UVF3NUtuVFo?oc=5" target="_blank">How Can Radiopharmaceutical Therapies Reach Their Full Potential? Improving Dose Reporting and Phase I Clinical Trial Design</a>  <font color="#6f6f6f">ASCO Publications</font>

Read Full StoryMore like this
Getting to Clinical Trial Diversity
Applied Clinical Trialsgeneral

Getting to Clinical Trial Diversity

<a href="https://news.google.com/rss/articles/CBMijAFBVV95cUxOMVNYSkdUOU1XcFFUMGh1di1sOFJCd0VjUHZyNnI3emxDNVp5cnYtSlVYOTJVRS1DX2NSNDdZRkdhZ3BpQlowWDRBbXpySnFsTmphM3RPRHpNSUxpU2xlVGFzZDNuSmdjV2ZQLTNfYjd3OEU2czdFX0cxRUs1SC1XdFBMdjZEb0lCVnc3Zg?oc=5" target="_blank">Getting to Clinical Trial Diversity</a>  <font color="#6f6f6f">Applied Clinical Trials</font>

Read Full StoryMore like this
Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial
Naturegeneral

Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTFBOX1REejNUT2wwQlo1dGY0X0w1cnB1blg3aXMwVktDVkVrN091emMzdnBDb2d2TGtpQUJrZ2R2cVA2LVpNWElETjJLOTFHcWowUEV2WDA1VW9WbTFWU0ZF?oc=5" target="_blank">Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
The Impact of DEI Ban On Clinical Research Ecosystem
Applied Clinical Trialsgeneral

The Impact of DEI Ban On Clinical Research Ecosystem

<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxQZkRNQTlWM2ZjRVRzVXBORVBmZFZydDZZbmM4OG1zbW1KMTdnUWdaRjY0MzRqMmhsb2R1bVVvRUpMNXltYU1iUnRSa1ZYNDZRZXp0b1JVMnhBSENfcWVqUXF3cUhGSjg4cHJOeVMzakhCeGwxcW9hM3hoeWo2UjA2Ny1pMXNHTmJtaEpuVWRZa2tRNnh1VnZ5NnZBanpVX0JhRmtZ?oc=5" target="_blank">The Impact of DEI Ban On Clinical Research Ecosystem</a>  <font color="#6f6f6f">Applied Clinical Trials</font>

Read Full StoryMore like this
Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial
Natureworld

Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE5hNHBLcEl1dUs1b3lNQmVhYjRPekkwd2ZZTzM1Ty0tUjd0ZGlobUVpYTZWQWNvY2NyaHphY0lkNWJvbWxvckgybGx2TDdOUVlwYnBITW5FUnhMSjhnWVVV?oc=5" target="_blank">Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Efficacy of levothyroxine monotherapy in achieving clinical euthyroidism and its impact on weight loss in women with hypothyroidism and obesity | Scientific Reports
Naturegeneral

Efficacy of levothyroxine monotherapy in achieving clinical euthyroidism and its impact on weight loss in women with hypothyroidism and obesity | Scientific Reports

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE5mRFROaF9ZZkRKTV9rME1UczgwcC1kQ2sxTDczY1M3N1FjNHpHYXF1dHVxYkJZZWROX0RibG5tMnN2UmFnbUhjdzIwMjRicFNkMlJPLXJGdE1tOE5vcG1z?oc=5" target="_blank">Efficacy of levothyroxine monotherapy in achieving clinical euthyroidism and its impact on weight loss in women with hypothyroidism and obesity | Scientific Reports</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Achieving clinical success with BET inhibitors as anti-cancer agents | British Journal of Cancer
Naturegeneral

Achieving clinical success with BET inhibitors as anti-cancer agents | British Journal of Cancer

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE9mMEk2ODNoa21BZXpkYW9VMEM3aTZBbFVweW1LV3M1WkFnV2VMMFBMUS1TLVFoWmJGOFBUY3U4d3pVQk5BVDhTS3NPVGptUXJUTHlvdHBOdWEwR3JiaHVF?oc=5" target="_blank">Achieving clinical success with BET inhibitors as anti-cancer agents | British Journal of Cancer</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
ACHIEVE-4, the longest Phase 3 study of Lilly's Foundayo (orforglipron) to date, reaffirmed its cardiovascular and overall safety profile as well as consistent improvements across key measures of cardiometabolic health
Eli Lillyscience

ACHIEVE-4, the longest Phase 3 study of Lilly's Foundayo (orforglipron) to date, reaffirmed its cardiovascular and overall safety profile as well as consistent improvements across key measures of cardiometabolic health

<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxOamlsMWI5a1daZExPUWRHS2tuZ19Wb0w3aXE0TXdvbjlxa2hic3ZjUEFlUWVGZTVmdVBjVzVrNWUxSXZrR094Sms0Wm1ET3ZWV2hJUGRRQXVNbU9PbVc4NTJWb2FzRlVlS0c4Qi1NQVNmbjY0b0k1QjU4TlZwSGZFRWZqTDh6a3lWalV0ZW9jQVhaWi0zeUVhUVhuYXBrU0xDTWJsd1BvWHhQNFlEMWRyZHp2SDNJR2dVMFVVbVJCbw?oc=5" target="_blank">ACHIEVE-4, the longest Phase 3 study of Lilly's Foundayo (orforglipron) to date, reaffirmed its cardiovascular and overall safety profile as well as consistent improvements across key measures of cardiometabolic health</a>  <font color="#6f6f6f">Eli Lilly</font>

Read Full StoryMore like this
Achieving Clinical Remission in Asthma Care, With Linda Rogers, MD
HCPLivegeneral

Achieving Clinical Remission in Asthma Care, With Linda Rogers, MD

<a href="https://news.google.com/rss/articles/CBMijgFBVV95cUxOZnhLamxLV2hHdHBzclNGRUlDeHhZVWJlX2pIWEdKNHFzOFg4RGVUM0t3T1Z3V19DNkZmYUhIbDR1RUJqRkc1ODJFdGNndURZb09NR3Q0dVN5OExoY3o1YjR5QUhlZHJDenRpbGRKMVdKQ2t3M3k4bFRldkkxc2MzZ3RESEtxaVRIYlJMeVBR?oc=5" target="_blank">Achieving Clinical Remission in Asthma Care, With Linda Rogers, MD</a>  <font color="#6f6f6f">HCPLive</font>

Read Full StoryMore like this
Elicio Therapeutics Reports ELI-002 7P Achieved Robust mKRAS-Specific T Cell Responses in 99% of Evaluable Patients in Ongoing Phase 2 AMPLIFY-7P Trial
Elicio Therapeuticsgeneral

Elicio Therapeutics Reports ELI-002 7P Achieved Robust mKRAS-Specific T Cell Responses in 99% of Evaluable Patients in Ongoing Phase 2 AMPLIFY-7P Trial

<a href="https://news.google.com/rss/articles/CBMikwJBVV95cUxQN2ZHRk1OQlZRanM1bTdIUHNub1FGUmI1SDRVVjliRkgzT281WmptanRRcnY5MHVfUnpmMkhSX3ZZcVNqQWFydjZmcHhkZjVad0xRa1VyaXBqbFpnanU3OVBEcDB6QWoydDhwN1IzOXIzRmVyeGpNSGJOc1pydHJId2s2Q3piSXFxZmJ4X0RwZ3BPZHFDYUw3RjNDcF9Bd20xU0RDWFJkZUI4dmhFNzRlbmpsME1mcmFrdkUtcmRGc0lQNXpxSUJRSlFhcmN6d1U5QlhucEswWk9kYVY0dzctOTk1S0FfRlhuZUF4aEE2UmpJNk1mbE5vdC1CZzZWS1BDUTQyNEVKX0l6b2hmczFqSzB3SQ?oc=5" target="_blank">Elicio Therapeutics Reports ELI-002 7P Achieved Robust mKRAS-Specific T Cell Responses in 99% of Evaluable Patients in Ongoing Phase 2 AMPLIFY-7P Trial</a>  <font color="#6f6f6f">Elicio Therapeutics</font>

Read Full StoryMore like this
Early Weight Loss and Other Factors Associated With Clinically Significant Weight Loss in Two Commercial Weight Loss Programmes
Wiley Online Librarygeneral

Early Weight Loss and Other Factors Associated With Clinically Significant Weight Loss in Two Commercial Weight Loss Programmes

<a href="https://news.google.com/rss/articles/CBMiakFVX3lxTE1vUTJPQldOOG1TUWRHbFpkWExlZkJHZXBpR1dveUtneXRHMzRRdTlRMWtaZnY1eDlhSXViWHNQcXlHLWEwSlpockkyQjl2MWNzQkdNSGlJMTE3M3lheHBGWlBJTmhuOXJWcXc?oc=5" target="_blank">Early Weight Loss and Other Factors Associated With Clinically Significant Weight Loss in Two Commercial Weight Loss Programmes</a>  <font color="#6f6f6f">Wiley Online Library</font>

Read Full StoryMore like this
Anti-obesity medication for weight loss in early nonresponders to behavioral treatment: a randomized controlled trial
Naturegeneral

Anti-obesity medication for weight loss in early nonresponders to behavioral treatment: a randomized controlled trial

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE1HaTBNbm90eXVVSlBfT2tqa0JqRkJEU0NSeGo2WEh5NjRvLUQxY0lIVVZZNlFpVzZvcmJPeTdTSlFxVE1HeEtlNXFHMkdVMU9CelZJSjJHcExZN0NDaGFR?oc=5" target="_blank">Anti-obesity medication for weight loss in early nonresponders to behavioral treatment: a randomized controlled trial</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Time to achieve optimal glycemic control and its determinants among diabetes mellitus patients receiving treatment: a retrospective study
Naturegeneral

Time to achieve optimal glycemic control and its determinants among diabetes mellitus patients receiving treatment: a retrospective study

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE5wQXRmUkxiRVFURGtRYmFqUDdCLTJ6VzROT2VneHBZcXJWSHRrUkpCc2dTMmtod1pKOWp3NHBvczNZZDdsQ0I1U3Y1RlBQRXpxeGVSR2VwSjlNdkxUeGFR?oc=5" target="_blank">Time to achieve optimal glycemic control and its determinants among diabetes mellitus patients receiving treatment: a retrospective study</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Fifty Percent of Patients with Ulcerative Colitis Treated with Mirikizumab Achieved Clinical Remission at One Year in Lilly's Pivotal Phase 3 Study
Eli Lillygeneral

Fifty Percent of Patients with Ulcerative Colitis Treated with Mirikizumab Achieved Clinical Remission at One Year in Lilly's Pivotal Phase 3 Study

<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxNX1RkM0xjaWEzV2hLUC1mbzhMUkZ3Z0ttUUVIeGwtWjlIUGFkYm9MeEVXN0tCUnExT3B2aTFNVU1TQkF3OHRYUkdDNmp0eGlRdXA5eVhhdEZ1UWs5M2pNY2FtODJJTENaZ2VCck5WbEJPMUZNLWN3NDUxQS1NeHA0ZXVPeXJ5V0tQWFZuVmdLNXRpTTh3a1hFRTgyZW9qRkh1cUdLTzIwTkl3OTZ3QXZtdTJaRmRkelV2N2JDRW1paHY?oc=5" target="_blank">Fifty Percent of Patients with Ulcerative Colitis Treated with Mirikizumab Achieved Clinical Remission at One Year in Lilly's Pivotal Phase 3 Study</a>  <font color="#6f6f6f">Eli Lilly</font>

Read Full StoryMore like this
STEP UP Trial Shows Higher Dose of Wegovy Produces Significant Weight Loss in Adults With Obesity Without Diabetes
Applied Clinical Trialsgeneral

STEP UP Trial Shows Higher Dose of Wegovy Produces Significant Weight Loss in Adults With Obesity Without Diabetes

<a href="https://news.google.com/rss/articles/CBMijAFBVV95cUxPdzNNeUJLUUJYdFVibnA0OVlBYmlHcVRtQW1xdE1CX2t1MEFXNkVUcVBMSUFUeDUzN2FxNUQ4dXhmYVF5OEcyLU5VSnFRM0JTVGVPMW9FUVpwVDdkd3RCTE8yZEVKaDItWUZlUVdpanhxRGdDeU4tSU5mcGlPMXQ5V2NSOUE1c0xaN3B1cQ?oc=5" target="_blank">STEP UP Trial Shows Higher Dose of Wegovy Produces Significant Weight Loss in Adults With Obesity Without Diabetes</a>  <font color="#6f6f6f">Applied Clinical Trials</font>

Read Full StoryMore like this
Machine learning generalizability across healthcare settings: insights from multi-site COVID-19 screening
Naturescience

Machine learning generalizability across healthcare settings: insights from multi-site COVID-19 screening

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE9rZk5YNVFCMmpuQ29HbmRnd0kwYUVEM1pod3VPVy12ODJoa3FDX3BmbjNDSmgzNTB4Vk5EaEJLbldDaHZpaDVoN3NRQWZKM0lqSlpuT1FZWl9DMlYxRjFZ?oc=5" target="_blank">Machine learning generalizability across healthcare settings: insights from multi-site COVID-19 screening</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
"Achieving clinically mean" — Live Google News Trends & Headlines